Class summary at a glance.

Every drug in the Penicillin-class Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $20.6Mcombined across class
Total Rx claims: 734K537K unique beneficiaries
Generic mfrs (active): 27across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ampicillin

Brand: AMPICILLIN · 34K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 1971-03-03

8 generic mfrs 90 plans require PA Discontinued

Low NADAC$0.458

→

Avg plan cost$0.458

Part D spend $7.0M 1× spread, current vs floor

Class share

34%

of class CY24 spend

View profile →

Penicillin V

681K Part D claims (CY24) · 526K beneficiaries · First FDA approval: 1990-09-30

4 generic mfrs 0 plans require PA

Low NADAC$0.044

→

Avg plan cost$0.081

Part D spend $4.2M 2× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Nafcillin

Brand: Nafcillin · 6K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 1989-10-31

5 generic mfrs 86 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $4.0M

Class share

20%

of class CY24 spend

View profile →

Oxacillin

Brand: Oxacillin · 5K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 1989-10-26

5 generic mfrs 104 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $3.2M

Class share

15%

of class CY24 spend

View profile →

Penicillin G

Brand: PENICILLIN G POTASSIUM · 7K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 1990-06-25

5 generic mfrs 64 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $2.2M

Class share

11%

of class CY24 spend

View profile →

Ampicillin and Sulbactam

Brand: Ampicillin and Sulbactam · — Part D claims (CY24) · First FDA approval: 1991-11-22

Brand-only (no generics) 80 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Piperacillin and Tazobactam

Brand: PIPERACILLIN AND TAZOBACTAM · — Part D claims (CY24) · First FDA approval: 2009-10-20

Brand-only (no generics) 0 plans require PA Discontinued

Low NADAC$3.49

→

Avg plan cost$3.49

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.